Ertugliflozin and incident obstructive sleep apnea: an analysis from the VERTIS CV trial

[1]  B. Zinman,et al.  The Impact of Empagliflozin on Obstructive Sleep Apnea and Cardiovascular and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial , 2020, Diabetes Care.

[2]  T. Taverner,et al.  Obstructive Sleep Apnea, a Risk Factor for Cardiovascular and Microvascular Disease in Patients With Type 2 Diabetes: Findings From a Population-Based Cohort Study , 2020, Diabetes Care.

[3]  J. Albrecht,et al.  Older adult US Medicare beneficiaries with untreated obstructive sleep apnea are heavier users of health care than matched control patients. , 2020, Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine.

[4]  Qin Sun,et al.  Effect of dapagliflozin on obstructive sleep apnea in patients with type 2 diabetes: a preliminary study , 2019, Nutrition & Diabetes.

[5]  M. Demura,et al.  Effect of sodium glucose cotransporter 2 inhibitors on obstructive sleep apnea in patients with type 2 diabetes. , 2018, Endocrine journal.

[6]  A. Lowe,et al.  Prevalence of obstructive sleep apnea in the general population: A systematic review. , 2017, Sleep medicine reviews.

[7]  Dorian Murariu,et al.  Trends in CPAP adherence over twenty years of data collection: a flattened curve , 2016, Journal of Otolaryngology - Head & Neck Surgery.

[8]  T. D. Bradley,et al.  Role of nocturnal rostral fluid shift in the pathogenesis of obstructive and central sleep apnoea , 2013, The Journal of physiology.

[9]  J. Concato,et al.  Obstructive sleep apnea as a risk factor for stroke and death. , 2005, The New England journal of medicine.

[10]  Naresh M Punjabi,et al.  Disorders of glucose metabolism in sleep apnea. , 2005, Journal of applied physiology.